Etiprednol dicloacetate (0-100 μg/kg, intranasal inhalation) attenuates peribronchial eosinophilia in the lung of the allergen sensitized and challenged rats[1].
Etiprednol dicloacetate (0.1 μg/kg, intranasal inhalation) inhibits eosinophil accumulation in rats (antigen-induced airway eosinophil infiltration)[3].
Etiprednol dicloacetate (0-20 mg/kg, p.o., 28 days) is well tolerated in rats and dogs[2].
| Animal Model: | Allergen sensitized and challenged Brown Norway rats[1] |
| Dosage: | 0.1, 1, 10, and 100 μg/kg |
| Administration: | Intranasal inhalation |
| Result: | Decreased the number of eosinophils at the perivascular area of the lung tissue.
Decreased the number of mucus secreting cells and antigen-induced formation of perivascular edema.
|